GSK3B and schizophrenia: Furthermore, bifeprunox was able to improve the negative symptoms of schizophrenia in clinical trials55 and it inhibited the activity of GSK3β in the present study, which further confirms that suppression of GSK3β activity is very likely to be associated with the effects of antipsychotics on the negative and cognitive symptoms of schizophrenia.